GLP-1 Vision Loss NAION Cases in 2026: Intake and Marketing Strategy for Plaintiff Firms

GLP-1 NAION mass tort marketing has emerged as one of the highest-priority acquisition strategies for plaintiff firms in 2026, driven by a consolidating claimant pool, a freshly formed MDL, and bellwether trials projected for 2026 to 2027. MDL 3176 is now active in the Eastern District of Pennsylvania, meaning the pre-bellwether window, historically the lowest-cost, highest-volume intake phase, is open but narrowing. Firms that build intake infrastructure and paid media campaigns now will acquire cases at materially lower cost per signed retainer than those who enter post-bellwether.

Why GLP-1 Vision Loss Is a Business Opportunity Right Now

NAION, non-arteritic anterior ischemic optic neuropathy, is sometimes called an optic nerve stroke. Blood supply to the optic nerve is suddenly blocked and the damage is irreversible. Vision loss is permanent. That combination of a severe, life-altering injury and a clear corporate defendant is exactly what drives high settlement values in mass tort litigation.

The causation science here is unusually strong for an emerging tort. A July 2024 study published in JAMA Ophthalmology, out of Mass Eye and Ear and Harvard, found semaglutide users with Type 2 diabetes had 4.28 times the NAION risk of comparable non-users. For obese semaglutide users, the risk multiplier jumped to 7.64 times. Those are large, statistically significant numbers from a peer-reviewed source with serious institutional credibility. Plaintiffs' counsel in MDL 3176 have a causation anchor that most emerging torts spend years trying to develop. It is already there.

The defendants are Novo Nordisk and Eli Lilly, two of the largest pharmaceutical companies in the world. The litigation theory is failure to warn. Both companies are alleged to have had ophthalmological risk signals and failed to update labeling. That is a well-worn path in mass tort litigation, and juries understand it.

For a plaintiff firm evaluating portfolio allocation right now, the core question is straightforward: strong science, large claimant pool, well-capitalized defendants, early MDL stage. The business case is compelling.

Litigation Landscape: What the MDL Timeline Means for Case Value and Timing

MDL 3176 was centralized in the Eastern District of Pennsylvania in late 2025 as a completely separate docket from MDL 3094, which handles GLP-1 gastrointestinal injury claims. That separation matters operationally because the two MDLs are at different stages and will move on different timelines. Firms already active in MDL 3094 should not assume they understand the 3176 track by analogy.

The judge assignment for MDL 3176 is still being finalized as of this writing. Discovery is beginning. Bellwether selection and trials are estimated in the 2026 to 2027 range. That means firms signing cases today are signing them 18 to 36 months before the first real settlement pressure appears, which is historically when case values are set and when firms holding large portfolios have the most leverage.

Pre-bellwether is the best time to build inventory. Once bellwether results start printing, whether positive or negative for plaintiffs, advertising costs spike, co-counsel competition intensifies, and the cost-per-signed-case number climbs significantly. Firms that are slow to act in 2026 will almost certainly pay two to three times more for the same case they could sign today.

There is no settlement on the table and none should be expected imminently. Any firm that needs near-term cash flow from this tort is entering for the wrong reasons. The right posture is: build a signed case portfolio now at current acquisition costs, hold it through discovery and bellwether, and position for a global resolution that historically rewards volume holders. The GI track had 10,000-plus active plaintiffs before the NAION track was even formed. This docket is growing rapidly and will be large.

Claimant Pool and Market Demand: Is There Still Volume to Capture?

More than 50 million GLP-1 prescriptions have been written in the United States. Semaglutide-based drugs, Ozempic and Wegovy from Novo Nordisk, are the primary focus, though tirzepatide products from Eli Lilly, Mounjaro and Zepbound, are also in scope. The qualifying population of people who used these drugs and subsequently developed NAION is enormous by any reasonable estimate.

NAION has a U.S. incidence of roughly 10 per 100,000 people per year in the general population. Apply even a modest risk multiplier to the tens of millions of GLP-1 users and the addressable claimant pool runs into the tens of thousands, potentially higher. The Harvard JAMA study used two independent patient cohorts to establish the risk elevation, which means the qualifying plaintiff population is not speculative. It is statistically derived from real-world prescription data.

Saturation right now is low. MDL 3176 is new, advertising has not yet flooded the major channels, and most consumers who experienced vision issues while on a GLP-1 drug have not yet connected their injury to the drug. That connection-gap is the acquisition opportunity. The window to reach these claimants before the market becomes competitive is 2026. Heavy plaintiff attorney advertising is expected throughout the year, and firms that delay until the second half of 2026 will face meaningfully higher CPLs and more intake competition.

Geographically, GLP-1 prescriptions are distributed broadly across the U.S. but slightly concentrated in states with higher rates of obesity and Type 2 diabetes, the Southeast, Midwest, and parts of the South. That geographic spread makes national digital advertising particularly effective for this tort, rather than relying on local TV or regional print.

GLP-1 NAION Mass tort Marketing: Advertising Economics and Channel Strategy

For a plaintiff firm thinking about acquisition math, here is the honest picture as the market stands in early 2026. Cost per lead on Facebook and Instagram for NAION vision loss claimants is currently running in a range that rewards early movers. As competition increases through the year, expect that number to rise. Signed case costs for a well-qualified NAION case with documented vision loss and a confirmed GLP-1 prescription history will likely land in a range that compares favorably to other pharmaceutical torts at a similar MDL stage.

Facebook and Instagram are the primary acquisition channels. The audience here is broad, middle-aged to older adults who were prescribed GLP-1 drugs for diabetes or weight management. That demographic over-indexes on Facebook. Creative angles that convert focus on the vision loss injury itself and the connection to the drug, without being sensational. Simple, clear copy that explains the drug connection and prompts someone who experienced sudden vision changes while on Ozempic or Wegovy to call or fill out a form. Video performs well. Testimonial-style creative is effective in this category.

Google search is a secondary channel, useful for capturing high-intent claimants who are already researching the connection. Programmatic display and YouTube pre-roll can support brand awareness at scale. The firms building volume efficiently in 2026 will use a multi-channel approach with Facebook as the workhorse.

At MTAA, we run campaigns on a transparent cost-plus model: ad spend plus a 15% agency fee, no hidden margins. With over $250 million in managed Facebook ad spend across 600-plus plaintiff law firms and more than 100 mass torts, our team has the data to launch this tort with calibrated budgets from day one rather than burning spend on learning curves.

Intake and Qualification: Screening Cases That Stick

Intake qualification for NAION cases requires confirming a short list of facts before a retainer is executed. First, the claimant must have taken semaglutide or tirzepatide, confirmed by prescription records or pharmacy history. Second, they must have received a diagnosis of NAION or been told by a physician that they experienced vision loss or optic nerve damage. Third, the diagnosis or vision event should have occurred during or after GLP-1 use, not years before the drug was ever prescribed.

The medical record burden here is real. NAION is diagnosed by ophthalmologists or neurologists, and those records need to exist before a case has real value. Intake teams should be collecting ophthalmology records, not just intake forms with self-reported symptoms. Firms building NAION portfolios should invest in a medical record retrieval workflow early, because the difference between a documented NAION case and a self-reported vision complaint is the difference between a case with value and a file that gets cut in discovery.

Retainer flow should be built for remote execution. The claimant pool is national, and DocuSign or a comparable e-signature tool combined with a clean retainer agreement that references MDL 3176 specifically will keep the process moving without geographic friction. AI-assisted intake tools are increasingly useful here for initial triage and for flagging cases that meet or miss the key criteria before they reach a human paralegal. If your firm is not already using AI in intake, the efficiency gap between you and firms that are is growing monthly.

How MTAA Approaches This Tort

We launched GLP-1 NAION campaigns as soon as the MDL was formed and the causation evidence was clear enough to support advertising responsibly. Our team treats this the same way we have approached every major pharmaceutical tort over the past 15 years: build the audience targeting based on the at-risk demographic, develop creative that connects the drug to the injury without overpromising outcomes, optimize CPL aggressively, and feed a qualified intake pipeline to the firm.

We work with firms on a full campaign management basis. Everything from creative production and audience strategy to budget pacing, lead delivery, and reporting. The cost-plus model means firms always know exactly what their ad spend is and exactly what our fee is. No margin hidden in media buying. That transparency matters when firms are evaluating a new tort and trying to model acquisition economics before committing budget.

For firms that want to understand how AI fits into the broader strategy for managing a GLP-1 NAION campaign, including AI-assisted intake, document review prep, and marketing automation, the frameworks I walk through in "A Lawyer's Guide to AI" apply directly to how plaintiff firms can run leaner, faster operations at scale.

The Window Is Open, But Not Indefinitely

The economics of GLP-1 NAION mass tort marketing favor firms that move in the first half of 2026. The MDL is new, the claimant pool is large and largely unaddressed, the causation science is the strongest of any current emerging tort, and advertising costs have not yet been driven up by the competitive surge that is coming. Firms that understand GLP-1 NAION mass tort marketing as a strategic investment in a pre-bellwether docket will build portfolios at acquisition costs that look very attractive by the time global resolution discussions begin. Firms that wait for more certainty will pay for that certainty in higher CPLs and a less favorable competitive position.

The opportunity in GLP-1 NAION mass tort marketing is real, the timing is right, and the infrastructure to run it at scale is available now. The question is whether your firm is building inventory today or planning to play catch-up in 2027.